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Abstract
First-line treatment of small cell lung cancer (SCLC) with combination chemotherapy consisting of cis-
diamminedichloroplatinum(II) (cisplatin) and etoposide is frequently followed by early relapses and a dismal prog-
nosis. Survival of a fraction of tumor cells and development of chemoresistance may be influenced by an initial
cellular stress response against the administered xenobiotics. Therefore, we compared the short-term effects of
cisplatin and non–cross-resistant bis-[(p-methoxybenzyl)cyclopentadienyl] titanium(IV) dichloride (Titanocene Y)
on phosphorylation of 46 sites of a total of 38 signaling proteins in tumor suppressor protein 53 (p53)–wild-type
NCI-H526 SCLC cells. The functional significance of selected kinases for the cytotoxicity of both drugs was tested
using specific inhibitors and an activator. The cisplatin-induced cellular stress response involved activation of
p38α mitogen-activated protein kinase, whereas Titanocene Y–triggered signaling affected c-Jun N-terminal ki-
nase. Phosphorylation of adenosine monophosphate (AMP)-activated protein kinase α1 (AMPKα1) was increased
by both drugs, which promoted cell survival, as indicated by results obtained using AMPK inhibitor compound C
and AMPK activator 5-aminoimidazole-4-carboxamide 1-β-D-ribofuranoside. This is in good agreement with previous
reports, where AMPKα1 was demonstrated to represent an important factor for the sensitivity to cisplatin in colon and
ovarian cancers, most likely by induction of autophagy. Thus, AMPKα1 constitutes a potential target to be exploited for
chemotherapeutic treatment of SCLC to circumvent resistance to metal-based compounds.
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Introduction
Current mainstay of treatment of patients with advanced cancer is
chemotherapy, and cis-diamminedichloroplatinum(II) (cisplatin), in-
troduced into the clinics in the 1970s, is still a well-proven anticancer
agent [1]. The established standard of therapy for patients with small
cell lung cancer (SCLC), the leading cause of cancer deaths world-
wide, is to use a platinum-based agent like cisplatin along with a second
chemotherapeutic drug, such as etoposide, docetaxel, gemcitabine, pe-
metrexed, or vinorelbine [2]. However, crucial drawbacks of platinum-
based drugs like cisplatin for anticancer therapy that limit their
applicability are side effects such as nephrotoxicity, emetogenesis,
neurotoxicity, and occurrence of both inherent and acquired resistance
to the drug [3,4]. Resistance may be caused by various mechanisms,
i.e., inhibition of drug uptake, inactivation by binding to metal-
lothioneins or glutathione, which is linked to increased export of the
cisplatin-glutathione conjugates by multidrug resistance protein 2, or
increased repair or replicative bypass of the cisplatin-DNA adducts,
respectively [3,5]. The cellular effect of cisplatin consists in formation
of interstrand and intrastrand DNA cross-links, which creates double-
strand DNA breaks and subsequently activates the cellular damage
response. Occurrence of bulky adduct-containing DNA is sensed
by the phosphoinositide-3 kinases DNA-dependent protein kinase,
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Rad3-related, respectively [6]. DNA damage signaling is commonly
transduced by cascades downstream of phosphoinositide-3 kinase/
AKT, tumor suppressor protein 53 (p53), and the mitogen-activated
protein kinases (MAPKs), i.e., extracellular signal–regulated kinase
(ERK), c-Jun N-terminal kinase (JNK), also termed stress-activated
protein kinase, and p38α/β/γMAPKs [3,7]. Whereas cisplatin triggers
induction of ERK, JNK, and p38 MAPK signaling in tumor cells,
JNK and p38 MAPK are differentially regulated in response to other
platinum-based drugs. Downstream of p38 MAPK or JNK, phos-
phorylated p53 activates caspases and induces apoptotic cell death
[8,9]. Generally, p53 controls both the G2/M and G1 cell cycle
checkpoints and mediates growth arrest, when DNA has sustained
damage, and activates DNA repair proteins. If the damage proves to
be irreparable programmed cell death is initiated by p53 [3,10].
To meet the demand for novel drugs that offer the therapeutic po-
tential to circumvent cellular resistance, coordination complexes with
central atoms apart from platinum, in particular transition metals
like titanium or ruthenium, lanthanum, copper, or silver have been
developed for in vitro and in vivo investigations [11]. A subclass of
organometallic compounds termed “metallocenes,” characterized by
a transition metal (M) central atom linked to cyclopentadienide
(Cp−/C5H5
−) ligands and the basic formula Cp2M, has gained in-
creasing interest as promising anticancer agents [12]. Ring-substituted
derivatives of titanocene dichloride (Cp2TiCl2) have demonstrated
considerable cytotoxicity in a broad spectrum of tumors in vitro
and in vivo, revealing highest activity for bis-[(p-methoxybenzyl)
cyclopentadienyl] titanium(IV) dichloride (Titanocene Y) with an
IC50 value of 5.5 μM, lying within the range of the IC50 value of cis-
platin (3.3 μM) [13–15]. Whereas cisplatin is known to damage DNA
directly, the mode of action of titanocenes has not been straightened
out so far [15]. It has been proposed that titanocenes may interfere with
gene transcription by direct interaction of titanium with DNA. In this
regard, expression of genes involved in cellular zinc uptake was down-
regulated and transcription of the members of the metallothionein 1
family was induced, as illustrated by treatment of NCI-H526 SCLC
cells with the derivative bis-[N,N-dimethylamino-2(N -methylpyrrolyl)
methylcyclo-pentadienyl] titanium (IV) dichloride (Titanocene C) and
whole-genome gene expression analysis [16]. Disturbed zinc homeo-
stasis may then be followed by cell cycle arrest and apoptosis because
of defects in transcription factors and accumulation of misfolded pro-
teins in the ER. Our present study aims at the elucidation of important
signal transduction proteins in NCI-H526 cells in response to short-
term exposition to Titanocene Y in comparison to cisplatin and to de-
fine cellular pathways, which could be responsible for the absence of
cross-resistance between the two compounds. Still, in the case of cis-
platin as the standard drug for the treatment of SCLC, only two reports
describe its effects on signaling phosphoproteins, i.e., JNK and c-Jun
in the SCLC cell line SHP77 and the AKT survival pathway in SW2,
H82, and U1285 cells, respectively [17,18].
Materials and Methods
Materials
Unless noted otherwise, all chemicals were purchased from Sigma-
Aldrich (St Louis, MO). The test compounds Titanocene Y (Figure 1)
and Titanocene C were synthesized and kindly provided by Prof.
M. Tacke (Dublin, Ireland) [19]. Stock solutions of Titanocene Y
and cisplatin were prepared in DMSO and phosphate-buffered saline
(PBS), respectively, and stored at −20°C.
The kinase inhibitors KRIBB3, SP600125, AR-A014418, PF-
573228, SC-68376, compound C, and Src inhibitor-1 were used to
investigate the functional roles of heat shock protein 27 (Hsp27),
JNK, glycogen synthase kinase 3α/β (GSK-3α/β), focal adhesion kinase
(FAK), p38α MAPK, AMP-activated protein kinase α (AMPKα),
and Src kinases, respectively. 5-Aminoimidazole-4-carboxamide 1-β-D-
ribofuranoside (AICAR) was applied as an activator of AMPK.
Cell Line and Culture Conditions
The NCI-H526 SCLC cell line was obtained from the American
Type Culture Collection (Rockville, MD). Cells were grown in suspen-
sion in RPMI-1640 bicarbonate medium (Seromed, Berlin, Germany)
supplemented with 10% FBS (Seromed), 4 mM glutamine, and anti-
biotics (10× stock formulated to contain ∼5000 U of penicillin, 5 mg
of streptomycin, and 10 mg/ml neomycin; Sigma-Aldrich), checked for
mycoplasma contamination (Mycoplasma PCR ELISA; Roche Diag-
nostics, Vienna, Austria), and subcultured twice a week. DNA profil-
ing by short tandem repeat analysis of the NCI-H526 cells proved their
identity to the American Type Culture Collection specifications, and
the yeast p53 functional assay revealed expression of fully active p53
(functional assay of separated alleles in yeast FASAY; data not shown).
Chemosensitivity Assays
Cells (1 × 104) in 100 μl of medium per well were distributed in
96-well microtiter plates (Greiner, Kremsmuenster, Austria) and test
substances were added in another 100 μl. The test compounds were
serially diluted in two-fold steps in triplicate. The microtiter plates were
incubated under tissue culture conditions (37°C, 5% CO2, 95%
humidity) for 4 days and cell viability was measured using a modified
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay (EZ4U; Biomedica, Vienna, Austria). This assay quantifies mito-
chondrial activity of the cells and therefore their viability by genera-
tion of a formazan dye from tetrazolium salt through mitochondrial
reduction. Optical density was measured using a microplate reader
(Eurogenetics, Brussels, Belgium) at 450 nm with an empty well as
reference. Values obtained from control wells containing cells and
media alone were set to 100% proliferation.
To test for effects of selected kinase inhibitors and an AMPK activa-
tor on cytotoxic activities of cisplatin and Titanocene Y, we performed
cytotoxicity tests of these compounds as described above using cells
incubated either in medium alone or in medium supplemented with
fixed concentrations of kinase inhibitors/activator. The doses of the
kinase inhibitors had been selected according to their IC80 values
determined previously. The percentage of viable cells in medium with-
out inhibitor/activator was subtracted from the percentage of viable
cells in the presence of the inhibitor/activator, and the mean value of
these differences over the whole concentration range tested is presented
as inhibitory/stimulatory activity of JNK inhibitor SP600125, p38α
Figure 1. Molecular structure of Titanocene Y.
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MAPK inhibitor SC-68376, GSK-3 inhibitor AR-A014418, AMPK
inhibitor compound C, and AMPK activator AICAR, respectively.
Cell Cycle Analysis
Cells (1 × 106 per well) were incubated with the test compounds
in six-well plates for 4 days. Harvested cells were washed with PBS
and fixed with 70% ethanol at −20°C for 30 minutes, washed again,
transferred into staining solution (20 μg/ml propidium iodide (PI),
5 μg/ml ribonuclease A, and 0.05% Nonidet P40 in PBS), and incu-
bated at room temperature overnight. Washed cells were analyzed
by acquisition of 1 × 104 cells in flow cytometry (Cytomics FC500;
Beckman Coulter, Krefeld, Germany) at excitation and emission
wavelengths of 488 and 675 nm, respectively. The proportion of
apoptotic sub-G1 cells was obtained from the logarithmic PI histo-
grams and percentages of cells in cell cycle phases G1/0 (resting), S
(DNA synthesis), and G2M (mitotic) were calculated from the linear
PI histograms using the MultiCycle AV software (Phoenix Flow
Systems, San Diego, CA). Experiments were done in duplicate.
Apoptosis Assay
The occurrence of apoptotic/necrotic cells was assessed by annexin V
(AnnV)/PI double staining experiments. Cells (5 × 105), incubated
either in medium alone or pretreated with the respective test substance,
were harvested and labeled using the Annexin V–fluorescein isothio-
cyanate (FITC) Apoptosis Detection Kit from Sigma-Aldrich according
to the manufacturer’s instructions. Following incubation at room tem-
perature for 10 minutes, cells were washed with PBS, labeled with PI
(final concentration of 10 μg/ml), and immediately analyzed by flow
cytometry. Proportions of intact/viable, apoptotic, late apoptotic/
necrotic, or necrotic cells were obtained as AnnV−/PI−, AnnV+/PI−,
AnnV+/PI+, or AnnV−/PI+ dot plots, respectively.
Indirect Immunofluorescence Tests
To test for expression of p53, we harvested cells by trypsinization. PBS-
washed cells were fixed in 70% ethanol at −20°C for 30 minutes and
washed again (Eppendorf centrifuge, 12,000 rpm, 5 minutes) before
staining with the respective antibody. Native cells (4 × 105) were incu-
bated with primary mouse monoclonal antibodyDO-1 inmedium (1:50)
in microtiter plates (Greiner) at 4°C overnight. Thereafter, cells were
stained with goat anti-mouse FITC-labeled IgG secondary antibody at
a dilution of 1:50 (4°C, 20 minutes), washed again, and analyzed by flow
cytometry. Antigen expression was calculated as relative fluorescence
intensity = mean fluorescence antibody/mean fluorescence control.
Determination of Patterns of Protein Phosphorylation
Relative protein phosphorylation levels of 38 selected proteins were
obtained by profiling of 46 specific phosphorylation sites using the
Proteome Profiler Human Phospho-Kinase Array Kit ARY003 from
R&D Systems (Minneapolis, MN) according to the manufacturer’s
instructions. Briefly, cells were rinsed with PBS, 1 × 107 cells/ml lysis
buffer was solubilized under permanent shaking at 4°C for 30 minutes,
and aliquots of the lysates were stored frozen at −80°C. Membranes
with spotted catcher antibodies were incubated with diluted cell lysates
at 4°C overnight. Thereafter, cocktails of biotinylated detection anti-
bodies were added at room temperature for 2 hours. Phosphorylated
proteins were revealed using streptavidin-HRP/chemiluminescence
substrate (SuperSignal West Pico, Thermo Fisher Scientific, Rockford,
IL) and autoradiography films (Amersham Hyperfilm ECL, GE Health-
care Life Sciences, Buckinghamshire, United Kingdom). The resulting
spots were scanned and images were quantified using the ImageQuant
TL v2005 software (Amersham Biosciences, Buckinghamshire, United
Kingdom) and Microsoft Excel software. The specific phosphorylation
sites of the proteins investigated in this study covered by the proteome
profiler array are listed in Table 1.
Statistics
Statistical analysis was performed using two-tailed Student’s t test
for normally distributed samples (*P < .05 was regarded as statistically
significant). Values are shown as mean ± SD or SEM.
Results
Cytotoxic Effects of Cisplatin, Titanocene C, and Titanocene Y
in NCI-H526 Cells
To compare the cytotoxic effects of the two titanocene derivatives
Titanocene C and Titanocene Y with that of cisplatin, we incubated
Table 1. Specific Phosphorylation Sites of Proteins Covered by the Proteome Profiler Human
Phospho-Kinase Array Kit (ARY003).
Phosphoprotein Phosphorylation Site
Akt Ser473
Akt Thr308
AMPKα1 Thr174
AMPKα2 Thr172
Chk-2 Thr68
c-Jun Ser63
CREB Ser133
eNOS Ser1177
ERK1/2 Thr202/Tyr204, Thr185/Tyr187
FAK Tyr397
Fgr Tyr412
Fyn Tyr420
GSK-3α/β Ser21/Ser9
Hck Tyr411
Hsp27 Ser78/Ser82
JNK pan Thr183/Tyr185, Thr221/Tyr223
Lck Tyr394
Lyn Tyr397
MEK1/2 Ser218/Ser222, Ser222/Ser226
MSK1/2 Ser376/Ser360
p27 Thr157
p27 Thr198
p38α Thr180/Tyr182
p53 Ser15
p53 Ser392
p53 Ser46
p70 S6 kinase Thr229
p70 S6 kinase Thr389
p70 S6 kinase Thr421/Ser424
Paxillin Tyr118
PLCγ-1 Tyr783
Pyk2 Tyr402
RSK1/2 Ser221/Ser227
RSK1/2/3 Ser380/Ser386/Ser377
Src Tyr419
STAT1 Tyr701
STAT2 Tyr689
STAT3 Tyr705
STAT4 Tyr693
STAT5a Tyr694
STAT5a/b Tyr694/Tyr699
STAT5b Tyr699
STAT6 Tyr641
TOR Ser2448
Yes Tyr426
β-Catenin
CREB indicates cAMP-response element-binding protein; MSK1/2, mitogen- and stress-activated
kinase 1/2; PLCγ-1, phospholipase C, gamma 1; RSK1/2, ribosomal S6 kinase 1/2.
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NCI-H526 cells with 8 two-fold dilutions of either 0.8 to 96.0 μM
Titanocene C, 0.8 to 102.3 μM Titanocene Y, or 1 to 66.7 μM
cisplatin for 4 days (Figure 2). The cells proved to be sensitive to both
cisplatin (IC50: 12.0 ± 0.5 μM) and Titanocene Y (IC50: 30 ±
10 μM), whereas Titanocene C exhibited significantly lower cyto-
toxicity (IC50: 93 ± 7 μM). Activity ratios of the compounds amounted
to 2.5 for Titanocene Y versus cisplatin and 7.8 for Titanocene C
versus cisplatin. Thus, the cytotoxic activity of Titanocene Y was
approximately three times higher than that of Titanocene C.
Effects of Cisplatin and Titanocene Y on Cell Cycle
Distribution of NCI-H526 Cells
To assess alterations of cell cycle distribution induced by the test
compounds, we treated NCI-H526 cells with two-fold dilutions of
either 0.5 to 8.3 μM cisplatin or 0.8 to 102.4 μM Titanocene Y for
3 days and determined cell cycle distributions following PI staining
of the cells by flow cytometry (Figure 3). Treatment of the cells with
cisplatin resulted in a reduction of the proportion of cells in G1/0 and
S phases and increases in the G2M phase fraction (except at a con-
centration of 8.3 μM cisplatin, owing to a low number of viable cells
left). Unlike cisplatin, treatment with Titanocene Y led to significant
growth arrest in S phase at a medium concentration as well as in G1/0
phase at 51.2 μM. Exceeding concentrations were not evaluated,
because only a low number of viable cells was remaining following
the incubation with the compounds.
AnnV Assay of the Induction of Apoptosis in Response
to Cisplatin and Titanocene Y
Investigation of the type of cell death was carried out by flow
cytometric analysis of NCI-H526 cancer cells following incubation
with cisplatin or Titanocene Y for 3 days and double labeling of the
treated cells with AnnV-FITC and PI. Figure 4 shows the proportions
of apoptotic or late apoptotic/necrotic cells, respectively, resulting from
drug treatment. The data indicate significant induction of apoptotic cell
death in NCI-H526 cells in response to 0.3 to 13.3 μM cisplatin and a
similar but less pronounced induction of apoptosis in response to 12.9
to 51.1 μMTitanocene Y, with highest toxicity at 102.2 μMof this drug.
Phosphorylation of Signaling Mediators in Response
to Cisplatin and Titanocene Y
To identify cellular signal transduction pathways involved in the
short-time effects of cisplatin and Titanocene Y on NCI-H526 cells,
46 specific Ser/Thr or Tyr phosphorylation sites of 38 selected
proteins were analyzed by phosphoprotein arrays. Therefore, NCI-
H526 cells were incubated with either 65 μM cisplatin or 102 μM
Titanocene Y for 6 hours and then subjected to analysis using the
respective array. Levels of the proteins with markedly altered phos-
phorylation obtained by normalization of the values to untreated
control cells are shown in Figure 5, A and B. The pattern of protein
phosphorylation was found to be significantly different for the two
test compounds, and a number of important signal transduction
mediators were involved. Phosphorylation levels of the following
proteins at their specific activation/inactivation sites were significantly
increased by Titanocene Y (Figure 5): Hsp27 (1.90 ± 0.28-fold over
control), lymphocyte-specific protein tyrosine kinase (Lck; 1.82 ±
0.24-fold over control), GSK-3α/β (1.52 ± 0.09-fold over control),
signal transducers and activators of transcription (STAT1, 1.51 ±
0.17-fold over control; STAT6, 1.44 ± 0.04-fold over control;
STAT5a/b, 1.41 ± 0.02-fold over control; and STAT3, 1.34 ± 0.17-
fold over control), and p27Kip1 protein (p27-Thr157; 1.17 ± 0.08-fold
over control). Protein kinase B (Akt-Ser473; 1.28 ± 0.34-fold over
control), Fgr kinase (Fgr; 1.16 ± 0.27-fold over control), and FAK
(1.13 ± 0.15-fold over control) exhibited increased phosphorylation
that was not statistically significant.
Figure 2. Dose-response curves for cisplatin, Titanocene Y, or
Titanocene C, respectively, obtained in NCI-H526 cells using MTT
proliferation assays. Values are presented as mean ± SD (n = 3).
Figure 3. Cell cycle alterations induced by treatment of NCI-H526
cells with either cisplatin or Titanocene Y at the indicated concentra-
tions. Values are presented as mean ± SD (n = 2). Differences to
control cells were statistically significant for cisplatin for G1/0 phase
for dilutions of 0. 52 to 2.75 μM versus control and for the S and G2M
phases over the whole concentration range, except at 8.3 μM,
versus control. Differences to control cells were statistically signifi-
cant for Titanocene Y for G1/0 phase at 51.2 μM, for S phase over the
whole concentration range, and for G2M phase for all concentra-
tions, except 51.2 μM Titanocene Y.
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In contrast to Titanocene Y, cisplatin reduced phosphorylation
levels of Hsp27 (0.36 ± 0.21-fold over control), Lck (0.66 ± 0.16-
fold over control), JNKpan (0.88 ± 0.08-fold over control), GSK-3α/β
(0.49 ± 0.04-fold over control), Akt (Ser473; 0.65 ± 0.10-fold over
control), STAT1 (0.28 ± 0.05-fold over control), STAT6 (0.65 ±
0.05-fold over control), STAT5a/b (0.80 ± 0.05-fold over control),
STAT3 (0.37 ± 0.12-fold over control), p27 (Thr157; 0.57 ± 0.01-
fold over control), Fgr (0.64 ± 0.15-fold over control), and FAK
(0.14 ± 0.09-fold over control) significantly. Furthermore, phos-
phorylation of p38α MAPK was markedly increased in comparison
to Titanocene Y. With exception of Akt, all differences between
cisplatin- and Titanocene Y–treated cells were significant for this
first group of phosphoproteins (Figure 5). Most strikingly, phosphory-
lation of the stress kinases JNK and p38αMAPK in response to the two
drugs was opposed, i.e., each of those two kinases exhibited increased
phosphorylation by only one of the compounds, whereas phosphory-
lation was not altered following treatment with the other drug. In de-
tail, phosphorylation of JNK was enhanced 1.81 ± 0.2-fold over control
in Titanocene Y–treated NCI-H526 cells but marginally affected by
cisplatin, whereas p38α MAPK was 1.66 ± 0.19-fold over control
higher phosphorylated by cisplatin treatment but barely sensitive to
Titanocene Y.
Furthermore, Figure 6 depicts proteins with single-direction phos-
phorylation changes in response to either Titanocene Y or cisplatin,
respectively. In contrast to the first group of contrariwise modified
phosphoproteins shown above, these remaining proteins exhibited
concurrent changes in respect to increased phosphorylation of
AMPKα1, Fyn, Hck, Chk-2, and Lyn and decreased phosphoryla-
tion of all remaining proteins. For both groups of protein phosphor-
ylation patterns, all differences in the ratios between cisplatin- and
Titanocene Y–treated NCI-H526 cells were statistically significant,
with the exception of Akt and Fgr.
Furthermore, a number of proteins exhibited parallel phos-
phorylation following incubation of the cells with either cisplatin or
Titanocene Y. In detail, phosphorylation of AMPKα1 was 2.61-fold
increased by cisplatin and 2.64-fold by Titanocene Y, respectively.
Enhanced phosphorylation of Fyn (2.29 ± 0.17-fold over control),
Hck (2.01 ± 0.32-fold over control), and Lyn (1.27 ± 0.03-fold over
control) was significant in response to Titanocene Y; Fyn phosphory-
lation was increased following exposure to cisplatin (1.32 ± 0.31-fold
over control); however, this change did not reach statistical significance.
Similarly, Chk-2 phosphorylation was enhanced to 1.71 ± 0.49-fold
over control by Titanocene Y and 1.42 ± 0.41-fold over control by cis-
platin. TOR and MEK1/2 phosphorylation was significantly decreased
after treatment with cisplatin (TOR, 0.66 ± 0.11-fold over control;
MEK1/2, 0.63 ± 0.03-fold over control), whereas Titanocene Y affected
these proteins only to a minor degree (mitogen-activated protein
kinase kinase 1/2 [MEK1/2], 0.87 ± 0.15-fold over control; target of
rapamycin [TOR], 0.94 ± 0.16-fold over control). All other phospho-
proteins, except p70S6K in response to Titanocene Y, displayed de-
creased phosphorylation levels. Table 2 lists the remaining proteins
where phosphorylation was regulated in parallel for both cisplatin and
Titanocene Y. Analysis of all these proteins where phosphorylation was
altered in the same direction by both cisplatin and Titanocene Y fol-
lowed a linear regression (y = 1.0776x + 0.1598) and gave a significant
correlation with a coefficient of R2 = 0.8524 (P < .001).
Considerable decreases in phosphorylation of more than 90% of
control were furthermore observed for p53 for treatment with either
cisplatin or Titanocene Y (cisplatin: p53 Ser392, 0.02 ± 0.01-fold over
control; p53 Ser46, 0.01 ± 0.07-fold over control; p53 Ser15, 0.01 ±
0.07-fold over control and Titanocene Y: p53 Ser392, 0.08 ± 0.03-fold
over control; p53 Ser46, 0.06 ± 0.14-fold over control; p53 Ser15, 0.05 ±
0.10-fold over control).
Effects of Cisplatin and Titanocene Y on p53 Protein
Level of NCI-H526 Cells
The p53 protein level of NCI-H526 cells was quantified by indirect
immunofluorescence using the DO-1 mouse monoclonal antibody that
recognizes an N-terminal epitope between amino acid residues 11 to 25
of wild-type and mutant p53. Comparisons between untreated and
drug-treated SCLC cells revealed a reduction of the protein levels of
p53 of 82% and 79% in response to the 6-hour exposure to cisplatin
and Titanocene Y, respectively (data not shown).
Effects of Kinase Inhibitors and an AMPK Activator on
Cytotoxic Activities of Cisplatin and Titanocene Y
against NCI-H526 Cells
The functional roles of Hsp27, JNK, GSK-3α/β, FAK, p38α
MAPK, AMPKα, and Src kinases in regard to the cytotoxic activities
of cisplatin and Titanocene Y against NCI-H526 cells were tested using
the inhibitors KRIBB3 (6.3 μM), SP600125 (12.0 μM), AR-A014418
Figure 4. AnnV assay of the induction of apoptotic cell death in
NCI-H526 cells in response to cisplatin (top) and Titanocene Y
(bottom). Columns depict the proportion of viable, apoptotic, late
apoptotic/necrotic, and necrotic cells, respectively, following ex-
posure to the indicated concentrations of the drugs. All differences
in the percentage of populations to the untreated control cells are
statistically significant for cisplatin and Titanocene Y. At a con-
centration of 102.2 μM Titanocene Y, the proportion of apoptotic
cells was significantly increased in relation to the other concentra-
tions tested.
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(12.0 μM), PF-573228 (0.6 μM), SC-68376 (6.0 μM), compound C
(1.25 μM), and Src inhibitor-1 (0.6 μM), as well as AICAR (5.0 μM),
an agent that stimulates AMPK activity (Figure 7). IC50 values
for the respective compound in NCI-H526 cells were >1.0 mM
for AICAR, >50 μM for AR-A014418, SP600125, SC-68376,
and KRIBB3, 6.3 μM for compound C, and 2.5 μM for both Src
inhibitor-1 and PF-573228, respectively.
Inhibition of p38α MAPK and Src kinases as well as activation of
AMPKα decreased the cytotoxic effect of cisplatin, which indicates a
death-promoting activity of the two former kinases and a protective
Figure 5. Relative levels of protein phosphorylation (ratios of phosphorylation of treated cells/untreated cells) for the panel of proteins
exhibiting opposingmodification in response to either cisplatin or Titanocene Y in NCI-H526 cells. With exception of p38αMAPK, all proteins
revealed increased phosphorylation in response to Titanocene Y, whereas cisplatin yielded decreased or unchanged phosphorylation (all
differences significant, except for Akt-Ser473 and Fgr). Phosphorylation levels of all proteinswere different from a ratio r=1.0, with exception
of JNKpan for cisplatin and p38α MAPK for Titanocene Y, respectively.
Figure 6. Relative levels of protein phosphorylation (ratios of phosphorylation of treated cells/untreated cells) for the panel of proteins
exhibiting concurrent modifications in response to either cisplatin or Titanocene Y in NCI-H526 cells.
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role for AMPKα. Accordingly, inhibition of AMPKα by compound C
reduced the cytotoxicity of cisplatin, and a similar effect was detected
for the inhibition of FAK. The cytotoxic effect of Titanocene Y was
impeded by the activities of Hsp27, FAK, AMPKα, and Src kinases,
whereas phosphorylation of JNK and GSK-3α/β resulted in increased
cell death. Thus, the main kinases regulated differently, which promote
the cytotoxicity of cisplatin and Titanocene Y, respectively, are p38α
MAPK and JNK, whereas the main effectors of resistance seem to be
FAK and AMPKα for both chemotherapeutics, as well as Hsp27 and
Src kinases in the case of Titanocene Y.
Discussion
In two thirds of SCLC patients, disease has already disseminated at
time of presentation, and although these tumors are highly sensitive to
first-line cytotoxic therapy, the rapid appearance of chemoresistance/
radioresistance results in early relapses and low survival rate [36]. Clinical
trials of new agents have been disappointing, and still, platinum- and
vepeside-based regimens are the standard therapy [2]. Cisplatin, dis-
playing clinical activity against a wide variety of solid tumors, is one
of the most potent antitumor agents employed [1]. The aim of the pres-
ent work was to study the cisplatin-triggered signaling in the p53–wild-
type SCLC cell line NCI-H526 derived from a bone metastasis of a
patient before therapy in respect to pathways that may be involved in
the development of resistance and to compare them with a titanocene
derivative that does not exhibit cross resistance to platinum drugs in
cancer cells [15]. We demonstrated that NCI-H526 cells were sensitive
to both cisplatin and Titanocene Y displaying IC50 values of 12 and
30 μM, respectively. Alteration in cell cycle distribution induced by
Titanocene Y, namely, arrest in the S and G1/0 phases, differs from
that of cisplatin, resulting in G2M arrest mainly. Application of both
chemotherapeutic drugs to NCI-H526 cells induced significant apopto-
tic cell death, with higher activity found for the platinum compound.
Next, we compared the short-term effects of both drugs on selected
mediators of signal transduction to detect putative distinctions in
their intracellular modes of action. Six-hour exposure of the cells with
the indicated concentrations of the compounds for subsequent as-
sessment using the phosphoprotein array aimed at matching with
the expected highest plasma concentrations in patients. According
to the literature, an intravenous bolus injection of 100 mg/m2 cis-
platin leads to an immediate peak blood level of 20 μM and a decrease
to 6.7 μM within 2 hours [20]. In contrast, pharmacokinetic studies
of Titanocene Y are still lacking. However, the pharmacokinetics of
a lyophilized formulation of titanocene dichloride (MKT4) gave a
biologic plasma half-life of 22.8 ± 11.2 hours and a Cmax of approx-
imately 30 μg/ml at a dose of 420 mg/m2 [21]. The NCI-H526 cells
were treated for a period of 6 hours with concentrations of cisplatin or
Titanocene Y that in both cases would have resulted in less than 10%
of survival in MTT assays after 4 days of incubation. Analysis of the
arrays of treated versus untreated cells revealed a set of inversely phos-
phorylated proteins with increased phosphorylation in response to
Titanocene Y, whereas phosphorylation was reduced in response to
cisplatin. Exceptions were elevated phosphorylation of p38α MAPK
in case of cisplatin and basal phosphorylation levels of both p38α
Table 2. Relative Phosphorylation (Treatment/Control) of Proteins Regulated in Parallel in
Response to Exposure of NCI-H526 Cells to Cisplatin and Titanocene Y.
Parallel Regulation Cisplatin Titanocene Y
Phosphorylated Protein Mean
SD
Mean
SD
AMPKα1 2.64 0.44 2.61 0.23 NS
Fyn 1.32 0.31 2.29 0.17 NS
Hck 1.12 0.18 2.01 0.32 NS
Chk-2 1.42 0.41 1.71 0.49 NS
Lyn 1.01 0.03 1.27 0.03 *
TOR 0.66 0.11 0.94 0.16 NS
MEK1/2 0.63 0.03 0.87 0.15 NS
STAT5a-Tyr694 0.58 0.02 0.80 0.01 *
STAT2 0.47 0.08 0.74 0.11 NS
STAT5b-Tyr699 0.83 0.03 0.67 0.02 *
p70S6K-Thr389 0.22 0.16 0.67 0.45 NS
CREB 0.87 0.02 0.63 0.05 *
STAT4 0.28 0.01 0.58 0.04 *
Pyk2 0.36 0.04 0.55 0.06 NS
PLC-γ1 0.30 0.01 0.54 0.03 *
RSK1/2 0.21 0.02 0.52 0.03 *
MSK1/2 0.34 0.02 0.50 0.02 *
eNOS 0.24 0.00 0.47 0.02 *
p70S6K-Thr229 0.23 0.04 0.46 0.09 NS
p70S6K-Thr421/Ser424 0.26 0.03 0.45 0.13 NS
Src 0.28 0.02 0.40 0.03 *
Paxillin 0.20 0.02 0.39 0.01 *
Yes 0.22 0.02 0.38 0.02 *
p27-Thr198 0.11 0.04 0.35 0.12 NS
AMPKα2 0.35 0.03 0.33 0.05 NS
Akt-Thr308 0.23 0.07 0.32 0.13 NS
ERK1/2 0.11 0.01 0.21 0.01 *
β-Catenin 0.23 0.00 0.21 0.01 NS
c-Jun 0.25 0.01 0.19 0.00 NS
RSK1/2/3 0.08 0.00 0.17 0.01 NS
p53-Ser392 0.02 0.01 0.08 0.03 NS
p53-Ser46 0.01 0.07 0.07 0.14 NS
p53-Ser15 0.01 0.07 0.05 0.10 NS
Ratios are presented as mean ± SD; NS, difference not significant.
*Difference significant, P < .05.
Figure 7. Effects of selected phosphoprotein inhibitors on the
cytotoxic activities of cisplatin and Titanocene Y. Assays were
performed using NCI-H526 cells and the two drugs in the absence
or presence of inhibitors (I) of Hsp27, JNK, GSK3α/β, FAK, p38α
MAPK, AMPK, and Src, as well as AMPK activator (A) AICAR.
Values represent the mean differences (± SEM) of cytotoxic activ-
ities in the presence and absence of the inhibitors/activator over
six concentrations of cisplatin or Titanocene Y. A positive difference
indicates increased survival of cells in the presence of the respec-
tive inhibitor/activator and the drug and a cell death–promoting
role of the phosphoprotein, whereas a negative difference indicates
an opposed effect on cell death of the respective phosphoprotein.
All differences to controls (0% change) were statistically significant,
except for KRIBB3, SP600125, and AR-A014418 in combination
with cisplatin.
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MAPK in response to Titanocene Y and JNK in response to cisplatin.
In general, increased phosphorylation of Hsp27, Lck, JNK, GSK-3,
STATs, and FAK is linked to higher resistance to platinum complexes
and other chemotherapeutics. In detail, expression of Hsp27 and
Hsp70, implicated in the mediation of antiapoptosis, was upregulated
in cisplatin-resistant ovarian tumor cell lines [22,23]. Aberrant ex-
pression or activation of Lck was reported for both lymphoid and
nonlymphoid malignancies [24]. Lck stimulates both tyrosine phos-
phorylation and DNA-binding activity of STAT5b, generally induced
in a variety of tumor cells. Activated Lck protects murine hemopoietic
BaF3 pro-B cells from interleukin-3 withdrawal-induced apoptosis
and is involved in fractionated radiation-induced expansion of the
CD133+ glioma-initiating cell population and in acquisition of resis-
tance to cisplatin and etoposide in glioma cells [25].
The three major pathways of MAPKs, namely, those involving JNK,
p38α MAPK, or extracellular signal-regulated kinase 1/2 (ERK1/2),
respectively, control cell proliferation, differentiation, and cell death.
JNK and p38α MAPK are key effectors of stress and inflammation
responses evoked by a variety of physical, chemical, and biologic stress
stimuli, whereas ERK1/2 is mostly induced by growth factors. Their
role in the response to cisplatin is complex as these proteins, in most
cases, are able to either induce or suppress apoptosis or to be irrelevant
in this process [26]. Cisplatin, as well as the less effective isomer trans-
platin, stimulated the activity of JNK in SCLC cells, i.e., the response
to trans-platin was rapid and transient, whereas JNK activation by cis-
platin was delayed and sustained [27,28]. One of the downstream tar-
gets of JNK is GSK-3α/β, a multifunctional Ser/Thr kinase negatively
regulated by phosphorylation of Ser9 [29]. Occurrence of pGSK-3β–
Ser9 cells was considerably enhanced in resistant CP70 compared to
native A2780 cells [30]. Inhibition of GSK-3α/β as indicated by in-
creased phosphorylation after treatment with Titanocene Y along with
enhanced activity of JNK plays a role in induction of the observed
apoptotic response of the NCI-H526 cells.
FAK protein expression was early downregulated in a testicular
tumor germ cell line by cisplatin, which thus failed to activate the
expression of the inhibitors of apoptosis, c-IAP-2 and XIAP, result-
ing in a defect in the abrogation of caspase activation [31]. Simul-
taneous knockdown of RelA and STAT5B sensitized tumor cells to
carboplatin treatment most effectively. Similarly, the nuclear factor-
kappa B (NF-κB) inhibitor BMS-345541 as well as the STAT5 inhibi-
tor dasatinib significantly enhanced sensitivity of the cells to carboplatin.
Furthermore, silencing of p27 enhanced the cytotoxic effect of cis-
platin, doxorubicin, and gemcitabine in both RMG-I and SMOV-2
ovarian cancer cells [32]. In conclusion, down-regulation of the pro-
tein phosphorylation in response to cisplatin in NCI-H526 cells
points to induction of apoptotic cell death, whereas up-regulation of
the phosphorylation of the same set of proteins following exposure to
Titanocene Y seems to be in favor of a partially antiapoptotic response.
The roles of JNK and p38αMAPK vary in different tumor entities, and
thus, their respective implications in the cytotoxic effects of cisplatin
or Titanocene Y cannot be generally deduced from this assessment of
phosphorylation solely.
A second group of phosphoproteins showed concurrent altera-
tions, namely, either increased or decreased phosphorylation, respec-
tively, in response to cisplatin and Titanocene Y. Most prominently
affected was AMPKα1, which regulates the energy balance system
by monitoring the intracellular energy status and confers resistance
to cisplatin [33–35]. Inhibition of the AMPK pathway sensitized
human leukemia K562 cells to doxorubicin [36]. Similarly, AMPK
was rapidly activated by cisplatin in AGS gastric cancer and HCT116
colon cancer cells, and compound C–mediated inhibition of AMPK
in those cells as well as in HCT116 xenografts resulted in a remark-
able increase in cisplatin-induced apoptosis [33]. From this, it was
concluded that AMPK fulfills a pivotal function for protection against
the cytotoxic effect of cisplatin. On the contrary, the AMPK activator
metformin suppressed growth and metastasis of ovarian cancer cells
with enhancement of the cytotoxicity of cisplatin in vivo [37,38].
Increases in cellular AMP and subsequent activation of AMPK in
response to cisplatin were primarily attributed to cellular damage by
reactive oxygen species (ROS). Furthermore, c-Src, a tyrosine kinase
involved in tumor proliferation, migration, and angiogenesis, was re-
ported to modulate the cytotoxic effect of cisplatin-induced DNA
damage [39]. Treatment with dasatinib abrogated Src phosphory-
lation in the majority of non–SCLC cell lines tested, with modest
effects on cell proliferation and survival. Moreover, cisplatin in com-
bination with dasatinib exhibited higher cytotoxicity in five cell lines
and blocked transcription of a panel of DNA repair genes. Addition-
ally, p70S6K and AKT/mammalian target of rapamycin (mTOR)
survival pathways were shown to play an important role in resistance
to cisplatin in human ovarian cancer cells [40]. A yeast complemen-
tation assay using our NCI-H526 cell extracts proved functional
p53 protein (data not shown). Furthermore, p53 underwent extensive
degradation in response to both compounds cisplatin and Titanocene
Y in these cells. Basically, levels of wild-type p53 are very low under
normal conditions; however, p53 was found to be highly phosphory-
lated in untreated NCI-H526 cells and became dephosphorylated
and degraded upon drug treatment. The present study aimed at a first
assessment of a large panel of phosphoproteins, and because the protein
content of the respective kinases was not measured, it has to be taken
into account that the observed alterations may be either because of a
variation in the number of phosphorylated sites or amount of expressed
protein. However, according to published reports, treatment of dif-
ferent cell lines with cisplatin for up to 24 hours did not alter protein
expression of p38αMAPK, JNK, and AMPKα [33,41,42].
In conclusion, most of the phosphoproteins that were hyper-
phosphorylated by Titanocene Y but hypophosphorylated by cisplatin
in NCI-H526 cells seem to counteract or promote apoptosis, respec-
tively, with the exception of JNK and p38α MAPK, which are acti-
vated by either cisplatin or Titanocene Y. To prove the specific roles
of Hsp27, JNK, GSK-3α/β, FAK, p38α MAPK, AMPKα, and Src
kinases in regard to survival of NCI-H526 cells, the effects of the re-
spective kinase inhibitors along with an activator of AMPKα on the
cytotoxicity of cisplatin and Titanocene Y were investigated. The ex-
periments indicated that JNK, activated by Titanocene Y, transmits
signals that result in NCI-H526 cell death, whereas p38α MAPK
fulfills an identical function for cisplatin. After exposure of a panel of
cell lines to cisplatin, doxorubicin, or taxol, respectively, it was merely
cisplatin that was capable of activating p38 MAPK, with two- to three-
fold higher stimulation of p38 MAPK compared to JNK [43]. There-
fore, the preferred induction of JNK versus p38α MAPK seems to be
linked to the specific DNA damage in response to Titanocene Y, which
does not involve double-strand breaks, in contrast to cisplatin [44]. In
addition to AMPKα, FAK plays a prosurvival role for both cisplatin and
Titanocene Y. The higher IC50 value of this titanocene compared to
cisplatin may be because of the activation of Hsp27 and Src kinases,
which have an antiapoptotic role. It should be stressed that the kinase
inhibitors employed basically affect phosphorylation sites of the respec-
tive target kinases and not their level of protein expression.
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In general, cisplatin like most metals, induces ROS and thus trig-
gers cell death, apart from its DNA damaging effect [45,46]. ROS
stimulate proapoptotic signaling molecules such as apoptosis signal-
regulating kinase 1, JNK, and p38 MAPK [47]. Transient low-level
activity of stress-activated protein kinases promotes cell proliferation,
whereas persistent, high-level activity results in cell death. In the
transformed cells, where basal stress signaling is potentiated com-
pared to normal cells, additional stress stimuli induce substantially
higher levels of ROS and stress kinase activity, which in turn aug-
ments the apoptotic response of those cells [48]. Because of an ele-
vated antioxidant capacity in advanced cancer cells, the ROS levels
decrease and stress kinase activity is suppressed, resulting in greater
stress resistance.
Stimulation of AMPK in cells exposed to anticancer drugs leads
to increased chemoresistance, and recent work has proposed a
mechanism of counteracting the cytotoxic action of the drugs by this
kinase. Dose- and time-dependent induction of autophagy was ob-
served in human U251 glioma, rat C6 glioma, and mouse L929
fibrosarcoma cells after treatment with cisplatin, as demonstrated
by up-regulation of autophagy-inducing protein beclin-1 and sub-
sequent appearance of acidic autophagic vesicles [49]. Inhibition of
autophagy with lysosomal inhibitors augmented cisplatin-triggered
DNA fragmentation and apoptotic cell death markedly. The induc-
tion of autophagy in cisplatin-treated cells was preceded by activation
of AMPK and concomitant down-regulation of mTOR-mediated
phosphorylation of p70S6 kinase. siRNA-mediated knockdown of
AMPK, just as the AMPK inhibitor compound C, increased cisplatin-
induced cell death, whereas silencing of mTOR, as well as the
AMPK activator metformin, protected cells from death in response
to cisplatin.
In summary, activation of AMPK seems to play an important role
in the antiapoptotic process in response to cisplatin and Titanocene Y
in the NCI-H526 SCLC cell line, which had been derived from a
bone metastasis from a patient before therapy. This is in good agree-
ment with reports on the role of AMPK on the effects of cisplatin and
doxorubicin in gastric and colon cancer cell lines, as well as a leukemia
cell line, respectively [33,36]. For both metal-based compounds in-
vestigated in the present study, cisplatin and Titanocene Y, activation
of AMPK was prominent and found to be a determinant of chemo-
sensitivity of NCI-H526 SCLC cells to the respective compound,
which was demonstrated functionally by the AMPK inhibitor com-
pound C and the AMPK activator AICAR, respectively. AMPK-
triggered autophagy may constitute a key mechanism, which protects
a fraction of the SCLC cells from first-line chemotherapy with
cisplatin and, presumably, other metal-based compounds and may
thus account for early regrowth of resistant tumor cells. Thus, inter-
ference with AMPK activation may represent an interesting thera-
peutic target to improve the outcome of metal-based chemotherapy
in different tumor entities. The efficacy of Titanocene Y seems to
be retarded or hampered by a partial induction of antiapoptotic sig-
naling, which, however, seems to be counterbalanced by proapoptotic
pathways, ultimately resulting in significant anticancer toxicity at
higher concentrations. Again, these findings underline differential
mechanisms of action of cisplatin and Titanocene Y.
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